Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies.
about
Ibrutinib: Implications for Use in the Treatment of Mantle Cell Lymphoma and Chronic Lymphocytic LeukemiaPhase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma.Immune independent crosstalk between lymphoma and myeloid suppressor CD14(+)HLA-DR(low/neg) monocytes mediates chemotherapy resistance.Targeting Wnt pathway in mantle cell lymphoma-initiating cells.Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK's Haematological Malignancy Research Network (HMRN).
P2860
Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Management of relapsed/refract ...... urrent therapeutic strategies.
@en
type
label
Management of relapsed/refract ...... urrent therapeutic strategies.
@en
prefLabel
Management of relapsed/refract ...... urrent therapeutic strategies.
@en
P2093
P2860
P50
P1433
P1476
Management of relapsed/refract ...... current therapeutic strategies
@en
P2093
Francesco Zaja
Massimo Federico
Umberto Vitolo
P2860
P304
P356
10.3109/10428194.2013.825903
P577
2013-08-31T00:00:00Z